MS drug treatment shows promise (AP)

EAST HANOVER, N.J. - Novartis Pharmaceuticals Corp., the U.S. unit of Swiss drugmaker Novartis AG, said Thursday that at least three out of four patients given an experimental multiple sclerosis treatment were free of relapses for more than two years. The company released data from a mid-stage clinical study showing that 77 percent of MS patients given the treatment FTY720 over two years remained free of relapses. Multiple sclerosis, which affects more than 2.5 million people worldwide, is an incurable ...